News and Announcements

GSK buys Boston's developmental liver disease drug for up to $2bn

By Benjamin Chiou

Date: Wednesday 14 May 2025

(Sharecast News) - GSK announced on Wednesday that it has entered into an agreement with Boston Pharmaceuticals to acquire its lead asset Efimosfermin for up to $2bn, buying a specialty medicine to treat and prevent progression of steatotic liver disease (SLD).
Under the terms of the deal, GSK pay Boston $1.2bn...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page